Creating High-Speed, High-Volume Fill-Finish
The last two years have shown the importance of both localized manufacturing and the need for flexible scale. That is one of the main drivers behind Fareva, a leading contract manufacturer with facilities across multiple continents, establishing a 10-year licensing agreement with ApiJect in December 2021.
As a multi-generational family-owned business, Fareva has developed a deep knowledge and appreciation for Blow-Fill-Seal (BFS), a rapid and efficient aseptic packaging process used for sterile pharmaceuticals and other liquid products.
Fareva, with support from France Relance – a €100 billion investment initiative into domestic manufacturing by the French government – identified ApiJect and its technology for expanding BFS into injectable medicines and vaccines as an opportunity to potentially build-on Fareva’s BFS capabilities and grow Europe’s fill-finish for vaccines and other injectables.
Olivier Dussopt, Minister Delegate for Public Accounts, said, “I am very happy that Fareva, and their manufacturing site of Annonay in Ardeche, invests in such a development project, concerning 3 production lines for an amount of 50 million euros. The government will support those investments with a program of 36,9 million euros. This is an excellent news for the local territory as it will create 150 jobs and this is also an excellent news for France and Europe that will benefit from this high technology for the manufacturing of pharmaceutical drugs and more precisely of vaccines.”
Fareva intends to install three Blow-Fill-Seal production lines that, when operational, will be able to fill-finish more than 500 million doses per year of vaccines and other large-molecule injectable drugs using ApiJect’s innovative prefilled injector technology. The new lines will be situated in Fareva Excelvision, located in Annonay, France, which has more than 50 years of experience manufacturing BFS containers and exporting products around the world.
BFS has demonstrated its ability to package certain vaccines and large-molecule formulations, and ApiJect is helping to expand BFS’s capabilities to additional drug products, including temperature-sensitive pharmaceuticals. When cleared by regulators, ApiJect will provide the necessary needle hub and other attachable components to convert finished BFS single-dose containers from these lines into easy-to-assemble, ready-to-use prefilled injectors.
ApiJect CEO and Chair Jay Walker commented, “This commitment by Fareva, with the support of the French Government, to expand fill-finish capacity is the right step at the right time. We are proud to partner with Fareva in bringing the next generation of injection technology to global health. Our mission at ApiJect is to support and execute a strategy of expanded distributed fill-finish capacity in the U.S. and regionally around the world.”
Read the Press Release
See the press release for this exciting announcement to learn more about how Fareva will be using ApiJect technology to expand their BFS capabilities for large-scale vaccine manufacturing at their Excelvision facility in France.
Learn More About How ApiJect is Using Blow-Fill-Seal
Learn more about the Blow-Fill-Seal aseptic packaging process for sterile liquid pharmaceuticals, and how ApiJect is working to expand BFS to fill-finish a wide rnage of injectable medicines and vaccines.